G. Shankar
Genentech · 17 works · 143 citations · h-index 6
Top works
- Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
- A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).
- 1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
- 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations
- 355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC
- P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab
- IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
- A Phase 1B Study to Evaluate the Safety and Pharmacology of the Dual PI3K-MTOR Inhibitor GDC-0980 in Combination with a Fluoropyrimidine, Oxaliplatin, and Bevacizumab (BEV) in Patients with Advanced Solid Tumors
- 9012 POSTER DISCUSSION A Phase lb Study to Evaluate the PI3-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- 365 A Phase 1b Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0941 in Combination with Erlotinib in Patients with Advanced Solid Tumors
- Effect of RGD-peptides on intracellular calcium and retractile responses in rat osteoclasts
- 335 POSTER Identification of potent, selective sphingosine-1-phosphate 1 receptor (S1P1R) antagonists with antitumor activity
- A Phase Ib Study to Evaluate the P13-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)
- TT01.01 Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy